社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
远离中概股A股股权
IP属地:江苏
+关注
帖子 · 500
帖子 · 500
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
远离中概股A股股权
远离中概股A股股权
·
06-09
美国总统毫无底线,上任后24小时解决俄乌问题🙋
37次“即将达成”!特朗普不断预告伊朗协议,却一次次落空
37次“即将达成”协议,0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定,但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出,此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时,宜维持较高的预期折扣系数。
37次“即将达成”!特朗普不断预告伊朗协议,却一次次落空
看
50
回复
评论
点赞
1
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
06-04
欧洲也开放,加上肺癌批准,估计这股能冲到100以上了
Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤
Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准,用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步,为当地晚期黑色素瘤患者提供了一种新的治疗选择。
Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤
看
263
回复
3
点赞
1
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
04-14
$伯克希尔B(BRK.B)$
不能因为价值投资就买它了 又一个教训
看
992
回复
评论
点赞
4
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
04-14
$伯克希尔B(BRK.B)$
不能因为价值投资就买它了 又一个教训
看
1,137
回复
评论
点赞
2
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
01-23
$伯克希尔B(BRK.B)$
价值投资,看着后面猛涨吧
看
2,151
回复
评论
点赞
2
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
01-13
也没有见你涨到60
诺和诺德:口服减肥药将进一步扩大GLP-1药物市场
格隆汇1月13日|诺和诺德首席执行官Mike Doustdar表示,减肥针剂Wegovy的口服版本,将令更多患者愿意使用相关药物,有助开拓尚未使用GLP-1药物的庞大患者群,进一步扩大相关市场。他表示,目前诺和诺德与礼来在美国合共仅向约1000万至1500万名患者销售GLP-1药物,但全美肥胖人口估计约1.1亿人,市场潜力庞大。
诺和诺德:口服减肥药将进一步扩大GLP-1药物市场
看
1,733
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
01-13
$拼多多(PDD)$
为啥最近跌这么多啊
看
1,756
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
01-12
开盘就是咋
@远离中概股A股股权:
$诺和诺德(NVO)$ 大家看这周能破60吗?
$诺和诺德(NVO)$ 大家看这周能破60吗?
看
1,144
回复
评论
点赞
1
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
01-12
$诺和诺德(NVO)$
大家看这周能破60吗?
看
2,944
回复
1
点赞
3
编组 21备份 2
分享
举报
远离中概股A股股权
远离中概股A股股权
·
01-12
$诺和诺德(NVO)$
好不容易涨下 结果遇到大盘不行 回调这么多
看
1,759
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3452505216401608","uuid":"3452505216401608","gmtCreate":1492529584078,"gmtModify":1734062313087,"name":"远离中概股A股股权","pinyin":"ylzggaggqyuanlizhonggaiguaguguquan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"LV3 头像框","vip":1,"status":2,"fanSize":23,"headSize":27,"tweetSize":500,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.66%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":1,"location":"江苏","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":14,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":573395599614056,"gmtCreate":1781018798221,"gmtModify":1781021178773,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"美国总统毫无底线,上任后24小时解决俄乌问题🙋","listText":"美国总统毫无底线,上任后24小时解决俄乌问题🙋","text":"美国总统毫无底线,上任后24小时解决俄乌问题🙋","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/573395599614056","repostId":"2642464134","repostType":2,"repost":{"id":"2642464134","kind":"highlight","weMediaInfo":{"introduction":"追踪全球财经热点,精选影响您财富的资讯,投资理财必备神器!","home_visible":1,"media_name":"华尔街见闻","id":"1084101182","head_image":"https://static.tigerbbs.com/66809d1f5c2e43e2bdf15820c6d6897e"},"pubTimestamp":1781003101,"share":"https://www.laohu8.com/m/news/2642464134?lang=zh_CN&edition=full","pubTime":"2026-06-09 19:05","market":"us","language":"zh","title":"37次“即将达成”!特朗普不断预告伊朗协议,却一次次落空","url":"https://stock-news.laohu8.com/highlight/detail?id=2642464134","media":"华尔街见闻","summary":"37次“即将达成”协议,0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定,但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出,此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时,宜维持较高的预期折扣系数。","content":"<html><head></head><body><blockquote><p>37次“即将达成”协议,0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定,但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出,此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时,宜维持较高的预期折扣系数。</p></blockquote><p style=\"text-align: left;\">当地时间6月9日,特朗普再度表示,美伊谈判已进入“最后关头”。</p><p style=\"text-align: left;\">据新华社,特朗普9日在纽约肯尼迪国际机场接受记者采访时说,“我们正处在最后关头,将达成一份非常、非常棒的协议”。<strong>当被问及谈判还需耗时多久,特朗普回答:“两到三天。”</strong></p><p style=\"text-align: left;\">然而,据媒体统计,过去两个多月间,<strong>特朗普已至少37次公开释放类似乐观信号</strong>。自4月7日宣布停火以来,其措辞从“非常接近协议”到“伊朗愿给一切”不断升级,<strong>但始终未见实质性成果落地</strong>。</p><p style=\"text-align: left;\">分析人士认为,<strong>此类反复出现的表态模式正削弱其市场参考价值</strong>。无论出于稳定金融市场考量,还是制造舆论压力推动谈判,缺乏具体进展支撑的口头信号,已引发投资者系统性降低敏感度。</p><h2 id=\"id_2290830803\" style=\"text-align: left;\">37次“即将达成”:一份未能落地的表态时间线</h2><p style=\"text-align: left;\">据CNN统计,自3月23日以来,<strong>特朗普已至少37次公开表示美伊协议“即将达成”或伊朗“迫切希望谈判”。</strong></p><p style=\"text-align: left;\">时间线显示,这一模式始于停火之前。3月23日,特朗普称双方已就“几乎所有要点”达成共识,但伊朗随即否认存在任何谈判。此后其措辞逐步升级:3月25日称伊朗“非常想达成协议”,3月26日称伊朗“在乞求达成协议”,3月29日则称“我确实预见到伊朗协议”。</p><p style=\"text-align: left;\">4月7日宣布停火后,<strong>特朗普将原定两周的谈判窗口描述为协议“最终确定”所需时间,但两周后协议并未落地</strong>。此后,他在4月15日、17日前后多次重申协议“非常接近”,4月30日又称伊朗“渴望达成协议”。</p><p style=\"text-align: left;\">进入5月,表态节奏未见放缓。5月18日,他以中东国家请求为由,将军事打击推迟“两三天”,理由是各方“认为非常接近达成协议”。5月23日,他表示协议“基本谈完,等待最终确认”,并称将“很快”宣布。5月28日,他在访谈中再次表示“接近一项非常好的协议”。</p><h2 id=\"id_3129771225\" style=\"text-align: left;\">信号失灵:反复口头表态侵蚀市场参考价值</h2><p style=\"text-align: left;\">特朗普本人在5月18日罕见承认此前预测落空:“我们曾有过几段时期,以为相当接近达成协议,但最终没有成功。”尽管他补充称“这次有些不同”,但后续走势再度证明情况并无实质变化。</p><p style=\"text-align: left;\">CNN分析指出,<strong>特朗普持续发出此类信号,或源于判断失误,或为稳定金融市场而有意为之,亦或试图通过反复表态将其“自我实现”。但无论动机如何,这一模式已严重侵蚀相关声明的市场信号价值。</strong></p><p style=\"text-align: left;\">对依赖地缘风险溢价定价的大宗商品及能源市场而言,单一政治表态已难以构成可靠的交易依据。在协议实质性落地之前,市场有充分理由对“即将达成”类口头声明维持较高的预期折扣。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>37次“即将达成”!特朗普不断预告伊朗协议,却一次次落空</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n37次“即将达成”!特朗普不断预告伊朗协议,却一次次落空\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1084101182\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/66809d1f5c2e43e2bdf15820c6d6897e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">华尔街见闻 </p>\n<p class=\"h-time\">2026-06-09 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><blockquote><p>37次“即将达成”协议,0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定,但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出,此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时,宜维持较高的预期折扣系数。</p></blockquote><p style=\"text-align: left;\">当地时间6月9日,特朗普再度表示,美伊谈判已进入“最后关头”。</p><p style=\"text-align: left;\">据新华社,特朗普9日在纽约肯尼迪国际机场接受记者采访时说,“我们正处在最后关头,将达成一份非常、非常棒的协议”。<strong>当被问及谈判还需耗时多久,特朗普回答:“两到三天。”</strong></p><p style=\"text-align: left;\">然而,据媒体统计,过去两个多月间,<strong>特朗普已至少37次公开释放类似乐观信号</strong>。自4月7日宣布停火以来,其措辞从“非常接近协议”到“伊朗愿给一切”不断升级,<strong>但始终未见实质性成果落地</strong>。</p><p style=\"text-align: left;\">分析人士认为,<strong>此类反复出现的表态模式正削弱其市场参考价值</strong>。无论出于稳定金融市场考量,还是制造舆论压力推动谈判,缺乏具体进展支撑的口头信号,已引发投资者系统性降低敏感度。</p><h2 id=\"id_2290830803\" style=\"text-align: left;\">37次“即将达成”:一份未能落地的表态时间线</h2><p style=\"text-align: left;\">据CNN统计,自3月23日以来,<strong>特朗普已至少37次公开表示美伊协议“即将达成”或伊朗“迫切希望谈判”。</strong></p><p style=\"text-align: left;\">时间线显示,这一模式始于停火之前。3月23日,特朗普称双方已就“几乎所有要点”达成共识,但伊朗随即否认存在任何谈判。此后其措辞逐步升级:3月25日称伊朗“非常想达成协议”,3月26日称伊朗“在乞求达成协议”,3月29日则称“我确实预见到伊朗协议”。</p><p style=\"text-align: left;\">4月7日宣布停火后,<strong>特朗普将原定两周的谈判窗口描述为协议“最终确定”所需时间,但两周后协议并未落地</strong>。此后,他在4月15日、17日前后多次重申协议“非常接近”,4月30日又称伊朗“渴望达成协议”。</p><p style=\"text-align: left;\">进入5月,表态节奏未见放缓。5月18日,他以中东国家请求为由,将军事打击推迟“两三天”,理由是各方“认为非常接近达成协议”。5月23日,他表示协议“基本谈完,等待最终确认”,并称将“很快”宣布。5月28日,他在访谈中再次表示“接近一项非常好的协议”。</p><h2 id=\"id_3129771225\" style=\"text-align: left;\">信号失灵:反复口头表态侵蚀市场参考价值</h2><p style=\"text-align: left;\">特朗普本人在5月18日罕见承认此前预测落空:“我们曾有过几段时期,以为相当接近达成协议,但最终没有成功。”尽管他补充称“这次有些不同”,但后续走势再度证明情况并无实质变化。</p><p style=\"text-align: left;\">CNN分析指出,<strong>特朗普持续发出此类信号,或源于判断失误,或为稳定金融市场而有意为之,亦或试图通过反复表态将其“自我实现”。但无论动机如何,这一模式已严重侵蚀相关声明的市场信号价值。</strong></p><p style=\"text-align: left;\">对依赖地缘风险溢价定价的大宗商品及能源市场而言,单一政治表态已难以构成可靠的交易依据。在协议实质性落地之前,市场有充分理由对“即将达成”类口头声明维持较高的预期折扣。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/627bc890436e46f74a0fe8143398a725","relate_stocks":{},"source_url":"https://wallstreetcn.com/articles/3774230","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2642464134","content_text":"37次“即将达成”协议,0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定,但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出,此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时,宜维持较高的预期折扣系数。当地时间6月9日,特朗普再度表示,美伊谈判已进入“最后关头”。据新华社,特朗普9日在纽约肯尼迪国际机场接受记者采访时说,“我们正处在最后关头,将达成一份非常、非常棒的协议”。当被问及谈判还需耗时多久,特朗普回答:“两到三天。”然而,据媒体统计,过去两个多月间,特朗普已至少37次公开释放类似乐观信号。自4月7日宣布停火以来,其措辞从“非常接近协议”到“伊朗愿给一切”不断升级,但始终未见实质性成果落地。分析人士认为,此类反复出现的表态模式正削弱其市场参考价值。无论出于稳定金融市场考量,还是制造舆论压力推动谈判,缺乏具体进展支撑的口头信号,已引发投资者系统性降低敏感度。37次“即将达成”:一份未能落地的表态时间线据CNN统计,自3月23日以来,特朗普已至少37次公开表示美伊协议“即将达成”或伊朗“迫切希望谈判”。时间线显示,这一模式始于停火之前。3月23日,特朗普称双方已就“几乎所有要点”达成共识,但伊朗随即否认存在任何谈判。此后其措辞逐步升级:3月25日称伊朗“非常想达成协议”,3月26日称伊朗“在乞求达成协议”,3月29日则称“我确实预见到伊朗协议”。4月7日宣布停火后,特朗普将原定两周的谈判窗口描述为协议“最终确定”所需时间,但两周后协议并未落地。此后,他在4月15日、17日前后多次重申协议“非常接近”,4月30日又称伊朗“渴望达成协议”。进入5月,表态节奏未见放缓。5月18日,他以中东国家请求为由,将军事打击推迟“两三天”,理由是各方“认为非常接近达成协议”。5月23日,他表示协议“基本谈完,等待最终确认”,并称将“很快”宣布。5月28日,他在访谈中再次表示“接近一项非常好的协议”。信号失灵:反复口头表态侵蚀市场参考价值特朗普本人在5月18日罕见承认此前预测落空:“我们曾有过几段时期,以为相当接近达成协议,但最终没有成功。”尽管他补充称“这次有些不同”,但后续走势再度证明情况并无实质变化。CNN分析指出,特朗普持续发出此类信号,或源于判断失误,或为稳定金融市场而有意为之,亦或试图通过反复表态将其“自我实现”。但无论动机如何,这一模式已严重侵蚀相关声明的市场信号价值。对依赖地缘风险溢价定价的大宗商品及能源市场而言,单一政治表态已难以构成可靠的交易依据。在协议实质性落地之前,市场有充分理由对“即将达成”类口头声明维持较高的预期折扣。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":571638367285488,"gmtCreate":1780584328648,"gmtModify":1780585431150,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"欧洲也开放,加上肺癌批准,估计这股能冲到100以上了","listText":"欧洲也开放,加上肺癌批准,估计这股能冲到100以上了","text":"欧洲也开放,加上肺癌批准,估计这股能冲到100以上了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/571638367285488","repostId":"1126068070","repostType":2,"repost":{"id":"1126068070","kind":"news","weMediaInfo":{"introduction":"全球快讯第一时间播报","home_visible":1,"media_name":"美股速递","id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1780517115,"share":"https://www.laohu8.com/m/news/1126068070?lang=zh_CN&edition=full","pubTime":"2026-06-04 04:05","market":"us","language":"zh","title":"Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1126068070","media":"美股速递","summary":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准,用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步,为当地晚期黑色素瘤患者提供了一种新的治疗选择。","content":"<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准,用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步,为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-06-04 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准,用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步,为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc.","BK4139":"生物科技"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126068070","content_text":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准,用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步,为当地晚期黑色素瘤患者提供了一种新的治疗选择。","news_type":1,"symbols_score_info":{"IOVA":1}},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3537417120281286","authorId":"3537417120281286","name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","crmLevel":7,"crmLevelSwitch":0,"idStr":"3537417120281286","authorIdStr":"3537417120281286"},"content":"肺癌早着呢,批准试验而已。","text":"肺癌早着呢,批准试验而已。","html":"肺癌早着呢,批准试验而已。"},{"author":{"id":"3537417120281286","authorId":"3537417120281286","name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","crmLevel":7,"crmLevelSwitch":0,"idStr":"3537417120281286","authorIdStr":"3537417120281286"},"content":"肺癌中期数据还没出,早着呢","text":"肺癌中期数据还没出,早着呢","html":"肺癌中期数据还没出,早着呢"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553545896220648,"gmtCreate":1776177679604,"gmtModify":1776177681374,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$ </a><v-v data-views=\"0\"></v-v> 不能因为价值投资就买它了 又一个教训","listText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$ </a><v-v data-views=\"0\"></v-v> 不能因为价值投资就买它了 又一个教训","text":"$伯克希尔B(BRK.B)$ 不能因为价值投资就买它了 又一个教训","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553545896220648","isVote":1,"tweetType":1,"viewCount":992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553546037388680,"gmtCreate":1776177647350,"gmtModify":1776177649497,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$ </a> 不能因为价值投资就买它了 又一个教训","listText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$ </a> 不能因为价值投资就买它了 又一个教训","text":"$伯克希尔B(BRK.B)$ 不能因为价值投资就买它了 又一个教训","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553546037388680","isVote":1,"tweetType":1,"viewCount":1137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":524972746403840,"gmtCreate":1769172010585,"gmtModify":1769172012266,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$ </a><v-v data-views=\"1\"></v-v> 价值投资,看着后面猛涨吧","listText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$ </a><v-v data-views=\"1\"></v-v> 价值投资,看着后面猛涨吧","text":"$伯克希尔B(BRK.B)$ 价值投资,看着后面猛涨吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/524972746403840","isVote":1,"tweetType":1,"viewCount":2151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":521299592986984,"gmtCreate":1768310407891,"gmtModify":1768310411350,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"也没有见你涨到60","listText":"也没有见你涨到60","text":"也没有见你涨到60","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/521299592986984","repostId":"2603579529","repostType":2,"repost":{"id":"2603579529","kind":"news","pubTimestamp":1768268932,"share":"https://www.laohu8.com/m/news/2603579529?lang=zh_CN&edition=full","pubTime":"2026-01-13 09:48","market":"us","language":"zh","title":"诺和诺德:口服减肥药将进一步扩大GLP-1药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2603579529","media":"格隆汇","summary":"格隆汇1月13日|诺和诺德首席执行官Mike Doustdar表示,减肥针剂Wegovy的口服版本,将令更多患者愿意使用相关药物,有助开拓尚未使用GLP-1药物的庞大患者群,进一步扩大相关市场。他表示,目前诺和诺德与礼来在美国合共仅向约1000万至1500万名患者销售GLP-1药物,但全美肥胖人口估计约1.1亿人,市场潜力庞大。","content":"<html><body><article><p>格隆汇1月13日|<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>首席执行官Mike Doustdar表示,减肥针剂Wegovy的口服版本,将令更多患者愿意使用相关药物,有助开拓尚未使用GLP-1药物的庞大患者群,进一步扩大相关市场。他表示,目前诺和诺德与<a href=\"https://laohu8.com/S/LLY\">礼来</a>在美国合共仅向约1000万至1500万名患者销售GLP-1药物,但全美肥胖人口估计约1.1亿人,市场潜力庞大。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德:口服减肥药将进一步扩大GLP-1药物市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德:口服减肥药将进一步扩大GLP-1药物市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 09:48 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113105654a713ba1a&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇1月13日|诺和诺德首席执行官Mike Doustdar表示,减肥针剂Wegovy的口服版本,将令更多患者愿意使用相关药物,有助开拓尚未使用GLP-1药物的庞大患者群,进一步扩大相关市场。他表示,目前诺和诺德与礼来在美国合共仅向约1000万至1500万名患者销售GLP-1药物,但全美肥胖人口估计约1.1亿人,市场潜力庞大。</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113105654a713ba1a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","BK4590":"PTP","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","BK4144":"石油与天然气的储存和运输"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113105654a713ba1a&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2603579529","content_text":"格隆汇1月13日|诺和诺德首席执行官Mike Doustdar表示,减肥针剂Wegovy的口服版本,将令更多患者愿意使用相关药物,有助开拓尚未使用GLP-1药物的庞大患者群,进一步扩大相关市场。他表示,目前诺和诺德与礼来在美国合共仅向约1000万至1500万名患者销售GLP-1药物,但全美肥胖人口估计约1.1亿人,市场潜力庞大。","news_type":1,"symbols_score_info":{"NVO":1.95}},"isVote":1,"tweetType":1,"viewCount":1733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":521302748737912,"gmtCreate":1768306035055,"gmtModify":1768306038832,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$ </a> 为啥最近跌这么多啊","listText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$ </a> 为啥最近跌这么多啊","text":"$拼多多(PDD)$ 为啥最近跌这么多啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/521302748737912","isVote":1,"tweetType":1,"viewCount":1756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":521010001940528,"gmtCreate":1768228406033,"gmtModify":1768228408280,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"开盘就是咋","listText":"开盘就是咋","text":"开盘就是咋","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/521010001940528","repostId":"520940309562576","repostType":1,"repost":{"id":520940309562576,"gmtCreate":1768203949000,"gmtModify":1768203951933,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a> 大家看这周能破60吗?","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a> 大家看这周能破60吗?","text":"$诺和诺德(NVO)$ 大家看这周能破60吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/520940309562576","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":520940309562576,"gmtCreate":1768203949000,"gmtModify":1768203951933,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a> 大家看这周能破60吗?","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a> 大家看这周能破60吗?","text":"$诺和诺德(NVO)$ 大家看这周能破60吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/520940309562576","isVote":1,"tweetType":1,"viewCount":2944,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":520838985995656,"gmtCreate":1768179217808,"gmtModify":1768179221204,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3452505216401608","authorIdStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a> 好不容易涨下 结果遇到大盘不行 回调这么多","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a> 好不容易涨下 结果遇到大盘不行 回调这么多","text":"$诺和诺德(NVO)$ 好不容易涨下 结果遇到大盘不行 回调这么多","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/520838985995656","isVote":1,"tweetType":1,"viewCount":1759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}